Cystic Fibrosis (CF) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034
Cystic Fibrosis (CF) Emerging Therapy
Thelansis’s “Cystic
Fibrosis (CF) Emerging Therapy, with Unmet Needs and TPP Insights Report
– 2024 To 2034″ provides a comprehensive analysis of the emerging
competitive landscape, unmet needs, target product profiles (TPPs), trial
designs, and KOL insights on key emerging therapies and key drug development
opportunities in the indication.
Cystic
Fibrosis (CF) Overview
Cystic Fibrosis (CF) is a serious,
life-shortening autosomal recessive genetic disorder caused by mutations in the
CFTR gene, resulting in a defective chloride and water channel that disrupts
fluid transport across epithelial cells. This core defect leads to the
formation of abnormally thick, sticky secretions that obstruct and damage
multiple organs, most critically the lungs (causing chronic infection,
inflammation, and progressive bronchiectasis) and the pancreas (leading to
insufficiency and malabsorption). Clinical presentation often begins in infancy
with a persistent cough, recurrent pulmonary issues, and poor growth, while an
elevated sweat chloride test and genetic analysis typically confirm diagnosis.
Treatment has been significantly advanced by CFTR modulators (like
elexacaftor/tezacaftor/ivacaftor), which target the underlying protein
malfunction in eligible patients, used alongside essential supportive care such
as airway clearance, antibiotics, and enzyme replacement therapy, all of which
are managed through lifelong, multidisciplinary care.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Read more: Cystic Fibrosis (CF) – Emerging Therapy, with Unmet
Needs and TPP Insights Report – 2024 To 2034
Comments
Post a Comment